A study to know the effect of low molecular weight heparin in treatment of acute pancreatitis.
Phase 3
Completed
- Conditions
- Health Condition 1: K859- Acute pancreatitis, unspecifiedHealth Condition 2: K852- Alcohol induced acute pancreatitisHealth Condition 3: K851- Biliary acute pancreatitisHealth Condition 4: K853- Drug induced acute pancreatitisHealth Condition 5: K850- Idiopathic acute pancreatitisHealth Condition 6: K858- Other acute pancreatitis
- Registration Number
- CTRI/2021/04/032665
- Lead Sponsor
- SMS Medical Jaipur
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 140
Inclusion Criteria
Patients of moderately severe or severe acute pancreatitis. Admitted within 24hours of onset of symptoms. willing to participate
Exclusion Criteria
Chronic pancreatitis. Traumatic pancreatitis. Hypersensitivity to low molecular weight heparin, heparin, pork products, benzyl alcohol or other ingredients of enoxaparin preparation or radio contrast agent. Any contraindication for low molecular weight heparin. Pregnancy and lactation. Charlson Comorbidity Index 5 or more
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pancreatic NecrosisTimepoint: Baseline and at the end of one week of treatment
- Secondary Outcome Measures
Name Time Method Clinical wellbeing(time taken to tolerate oral feeds, time of relief from abdominal symptoms and signs, mean duration of hospital stay)Timepoint: During the period of current episode of acute pancreatitis;Local and systemic complicationsTimepoint: During the period of current episode of acute pancreatitis;MortalityTimepoint: During the period of current episode of acute pancreatitis;Need for surgical, endoscopic or minimal invasive procedureTimepoint: During the period of current episode of acute pancreatitis